Filing summary: Calyxt, Inc. Form 10-Q
Entity note: Although the request metadata names Cibus, Inc., the supplied filing identifies the registrant as Calyxt, Inc. (Nasdaq: CLXT). This summary reflects the filing text.
Business context and reporting period
Unaudited results for the quarter and nine months ended September 30, 2017. Calyxt is an early-stage agricultural biotechnology company using gene-editing technology to develop specialty food ingredients and crop traits. It reported no product revenue; current revenue is primarily from research and development agreements. Cellectis owned approximately 79.8% at quarter-end.
Financial metrics
| Metric | Three months ended September 30, 2017 | Nine months ended September 30, 2017 |
|---|---|---|
| Revenue | $44,000 | $322,000 |
| Research and development expense | $6.438 million | $9.157 million |
| Selling, general and administrative expense | $6.553 million | $10.141 million |
| Operating loss | $12.947 million | $18.976 million |
| Net loss | $12.904 million | $19.131 million |
| Basic and diluted loss per share | $0.51 | $0.89 |
- Cash and cash equivalents were $62.545 million at September 30, 2017, versus $5.026 million at December 31, 2016. Current assets were $63.062 million and current liabilities $5.087 million.
- For the first nine months, operating cash outflow was $5.968 million and investing cash outflow was $1.614 million. Financing provided $65.101 million, including IPO proceeds and sale-leaseback proceeds.
- Total liabilities were $13.461 million, including a $7.934 million finance and capital lease obligation and $3.319 million due to related parties. Stockholders’ equity was $62.112 million.
- No gross margin comparison is meaningful: revenue was minimal and cost of revenue was zero in Q3 2017. Nine-month 2016 cost of revenue was $200,000; no comparable expense was recorded in 2017.
Material changes versus prior comparable periods
- Q3 revenue fell 58.1% year over year, from $105,000 to $44,000; nine-month revenue was nearly flat, down 1.5% to $322,000. Management attributed decreases to expired or terminated intellectual-property license contracts and a deliberate reduction in R&D contracts.
- Q3 operating expenses rose 401.6% to $12.991 million, and nine-month operating expenses rose 145.4% to $19.298 million. Increases reflected higher R&D activity, personnel and professional costs, and substantial stock-based compensation.
- Net loss widened to $12.904 million for Q3 from $2.507 million and to $19.131 million for nine months from $7.533 million. The 2017 results included substantial IPO-related stock compensation; total stock-based compensation was $9.191 million for Q3 and $9.634 million for nine months.
- The July 2017 IPO raised approximately $58.0 million net. The company sold 8.05 million shares at $8 per share, including 2.5 million shares purchased by Cellectis.
Outlook, risks, contingencies and unusual items
- Management expected IPO proceeds and available cash to fund operations through mid-2019, but cautioned that this estimate is uncertain and that additional funding may be needed. Cellectis separately guaranteed funding for operations through August 2018.
- The company expected continuing and increasing operating losses and expenses, and no material product revenue unless and until product candidates are developed and commercialized. Its first candidate, high-oleic soybean, was expected to be commercialized by the end of 2018; this is a forward-looking expectation, not a guarantee.
- A September 2017 sale-leaseback generated approximately $7 million. The related new headquarters lease is for 20 years, with four five-year extension options. Estimated annual base rent after construction is approximately $1.48 million, plus other net-lease costs. Cellectis guaranteed the lease; a November 10, 2017 agreement provides for Calyxt to indemnify Cellectis if Cellectis owns 50% or less of Calyxt.
- Approximately $1.6 million of seed and grain forward purchase commitments were not recorded because delivery had not occurred. The filing reported no material litigation requiring accrual or disclosure.
- Management said disclosure controls were not effective as of September 30, 2017, due to an ongoing material weakness involving review of forward-purchase derivative contracts. Remediation steps had begun but were not yet fully implemented and validated.
- Key risks include development and regulatory uncertainty, need for capital, competition, reliance on counterparties and Cellectis, consumer acceptance and evolving regulation of gene-edited products, agricultural and weather-related risks, and intellectual-property protection.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is for Calyxt, Inc., not Cibus, Inc.
- Track cash burn and actual runway against management’s mid-2019 estimate, including whether additional financing is required.
- Assess progress and timing of the high-oleic soybean and other product candidates, including field trials, regulatory requirements and commercialization readiness.
- Monitor recurring operating costs separately from the unusually large stock-based compensation charges and evaluate potential dilution from outstanding options and restricted stock units.
- Review the long-term headquarters lease obligations, related-party exposures, and the conditions and potential effect of the Cellectis lease guarantee and indemnity.
- Check whether management completes and validates remediation of the material weakness in controls over forward-purchase contracts.